Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.

× No keyword cloud information.

22 in total

1. Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib.

Authors: John M Goldberg; Tara Gavcovich; Gaurav Saigal; Jonathan W Goldman; Lee S Rosen
Journal: J Clin Oncol Date: 2014-02-18 Impact factor: 44.544

Review 2. Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.

Authors: Blanca Homet Moreno; Elena Garralda Cabanas; Ricardo Hitt
Journal: Clin Transl Oncol Date: 2010-07 Impact factor: 3.405

3. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.

Authors: Baorang Zhu; Jing Li; Qiaosheng Xie; Liyan Diao; Lvhua Gai; Wuwei Yang
Journal: Cancer Biol Ther Date: 2018-01-24 Impact factor: 4.742

4. Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines.

Authors: John M Goldberg; David E Fisher; George D Demetri; Donna Neuberg; Stephen A Allsop; Catia Fonseca; Yukoh Nakazaki; David Nemer; Chandrajit P Raut; Suzanne George; Jeffrey A Morgan; Andrew J Wagner; Gordon J Freeman; Jerome Ritz; Cecilia Lezcano; Martin Mihm; Christine Canning; F Stephen Hodi; Glenn Dranoff
Journal: Clin Cancer Res Date: 2015-03-24 Impact factor: 12.531

Review 5. The current management of alveolar soft part sarcomas.

Authors: Xiaojing Chang; Yuehong Li; Xiaoying Xue; Huandi Zhou; Liubing Hou
Journal: Medicine (Baltimore) Date: 2021-08-06 Impact factor: 1.817

6. Alveolar soft part sarcoma-radiologic patterns in children and adolescents.

Authors: Flore Viry; Daniel Orbach; Jerzy Klijanienko; Paul Fréneaux; Gaelle Pierron; Jean Michon; Sylvia Neuenschwander; Hervé J Brisse
Journal: Pediatr Radiol Date: 2013-05-17

7. Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.

Authors: David T Vistica; Melinda Hollingshead; Suzanne D Borgel; Susan Kenney; Luke H Stockwin; Mark Raffeld; David S Schrump; Sandra Burkett; Gary Stone; Donna O Butcher; Robert H Shoemaker
Journal: J Pediatr Hematol Oncol Date: 2009-08 Impact factor: 1.289

Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.